Japan Slides

Drug Development in Japan

Regulatory Authority for Drug Approval in Japan

  • There are two primary regulatory bodies responsible for reviewing and approving drugs and medical devices in Japan:

    • Pharmaceuticals and Medical Devices Agency (PMDA)

    • Ministry of Health, Labour, and Welfare (MHLW): Responsible for policy formulation.

Pharmaceuticals and Medical Devices Agency (PMDA)

  • Established: April 1, 2004.

  • Services Provided in Drug Regulatory:

    • Consultation Services:

    • Pharmaceutical affairs consultation on R&D strategy.

    • Clinical trial consultation.

    • Regulatory Review:

    • Pre-market review.

    • Re-examination and re-evaluation of drugs.

    • Use-results evaluation.

    • Compliance Assessments:

    • Includes GLP (Good Laboratory Practice), GCP (Good Clinical Practice), and GPSP (Good Post-marketing Study Practice).

    • Inspections and evaluations related to GMP (Good Manufacturing Practice), QMS (Quality Management System), and GCTP (Good Clinical Trial Practice).

    • Standards development for drug quality and safety.

    • Safety measures implementation.

    • Providing relief services for adverse health events.

PMDA's Safety Triangle

  • Components:

    • Securing Safety and Efficacy: Focus on risk reduction.

    • Three-pillar System: Unique approach in Japan consisting of:

    • Continuous risk mitigation efforts.

    • Relief measures for health damage caused by adverse drug reactions.

Post-marketing Safety Measures

  • Actions on Submitted Information:

    • Acceptance and organization of safety information provided by Marketing Authorization Holders (MAHs) or medical institutions.

    • Scientific research and analysis of collected information.

    • Consultation services regarding safety measures for MAHs and consumers.

    • Provision of safety information concerning drugs, medical devices, and regenerative medical products.

    • Product reviews, regulatory review of drugs and medical devices, as well as GMP/QMS/GCTP inspections and standards development like the Japanese Pharmacopoeia.

    • Relief services catered specifically for adverse drug reactions and infections from biological products.

Medical Product Development Process and PMDA's Services

  1. Research and Development.

  2. Non-clinical Tests:

    • General consultation on Regulatory Science and R&D strategy.

  3. Clinical Trials: Include phases from Pre-clinical to Post-marketing.

    • Filing of application and approval of clinical trials.

  4. Consultation Services Include:

    • Clinical Trial Consultation.

    • Epidemiological Study Consultation.

  5. Regulatory Review includes:

    • Pre-market Review.

    • GLP/GCP/GPSP Compliance Assessment.

    • GMP/QMS/GCTP inspections.

    • Safety measures assessments.

    • Relief services for adverse health effects.

Organization and Responsibility of PMDA

  • Duties Include:

    • Providing relief work for Drug Adverse Reactions (ADR).

    • Overseeing medical benefits and certain pensions.

    • Handling damage caused by ADR.

    • Conducting registrational reviews for drug approvals and guidance for clinical trials.

    • Ensuring compliance with GMP, GLP, and GCP regulations.

    • Gathering, analysing, and disseminating information regarding the quality, efficacy, and safety of drugs.

IND- Investigational New Drug

  • Refers to the First In Human study aspect of drug development in Japan and includes:

    • General drug development phases: Single Ascending Dose (SAD), Multiple Ascending Dose (MAD), Phase II, Phase III, and NDA (New Drug Application).

Clinical Trials in Japan

  • Standards:

    • The New GCP (Ordinance No. 28, GCP dated March 27, 1997) was enacted on April 1, 1997, based on ICH-GCP Guidelines (E6) to protect human rights, assure safety, and ensure reliability of clinical study data for both standard and post-marketing clinical trials.

  • Objectives of Clinical Studies:

    • Evaluate therapeutic and prophylactic efficacy of new investigational drugs for diseases or symptoms.

    • Assess risks and possible adverse drug reactions (ADRs) in humans to determine clinical usefulness based on efficacy and safety comparisons.

Clinical Trial Approval Process in Japan

  • Sequential Steps:

    • The sponsor must obtain Institutional Review Board (IRB) approval before applying for clinical trial approval with PMDA.

    • Initial notification and study protocol submission to PMDA is required prior to entering any contracts with institutions for trials.

    • PMDA implements a “Clinical trial consultation system” providing guidance on protocols, which sponsors are encouraged to use to reduce review time.

  • Timeline:

    • Approximately two months for consultation request.

    • Clinical trial approval is default; sponsors can commence trials if no queries arise in the specified time frame.

Clinical Trial Notification (CTN)

  • Mandatory Notification: Required submission to PMDA before conducting trials, aiming to ensure compliance with the Pharmaceutical and Medical Device Act.

  • Categories Under CTN:

    • Variants of drugs with differences in active ingredients, administration routes, combination ratios, or drugs not under the re-examination period.

Marketing Requirements for Drug Products

  • Drugs must be marketed by an entity holding an appropriate marketing authorization, and confirmations must show compliance with GMP standards.

  • Conditions for Approval:

    • Drugs must meet quality, efficacy, and safety standards to gain governmental permission for market distribution and healthcare use in Japan.

Data Submission Package Requirements

  • Compliance with ICH technical guidelines is essential, especially concerning ethnic factors in clinical studies.

  • CTD Structure:

    • Module 1: Regional Specific Documents;

    • Module 2: Global Documents modified for PMDA;

    • Module 3: Quality Data in English with PMDA-specific revisions;

    • Module 4 & 5: Nonclinical and Clinical Study Reports.

Typical Japan Development & Registration Routes

  • Routes Include:

    • Route-1: Participation in Global Phase 3 studies.

    • Route-2: Bridging Development.

    • Route-3: Full Local Development through all phases in Japan.

Registration Process for Foreign Products

  • Clinical Data Requirements: Include PK data, which must be presented separately and as part of Phase 3 results.

Registration Timeframe

  • Standard Review: Approximately 12 months from MAA submission.

  • Priority Review: For orphan or new drugs providing substantial contributions to healthcare, takes around 9 months.

Review Process Comparison (EU, US, JP)

  • Key Differences:

    • NMDA (New Drug Application) reviews take 12 months in Japan, while EU can be 13 to 15 months, and US generally takes around 10 months.

PMDA Consultation Types

  • Face-to-Face Advice before consultation for key product development discussions and Short Consultations for matters regarding generic agents.

Timelines for PMDA Consultation Meetings

  • Overall timelines amount to around 5-6 months for formal consultations; critical phases include negotiation periods and briefing package submissions 5-6 weeks prior to meetings.

Importance of PMDA Consultations

  • Benefits to Applicants:

    • Clarification and confirmation on development issues and reduced inquiries after submission.

    • Benefits to PMDA:

    • Understanding product status for preparation during reviews, ensuring adherence to submission requirements.

Development Process in Japan

  • Average duration of 2-10 years (typically 5 years), with phases including preclinical testing, clinical trials (Phases I to III), and various approvals for registration, monitoring, and re-evaluation.

Re-examination and Re-evaluation Processes

  • Post-marketing surveys necessary for new drugs to reaffirm safety and efficacy over specific re-examination periods.

  • The duration for re-examinations for drugs with new active ingredients is typically eight years.

Conclusion

  • Japan adheres to ICH guidelines and CTD format, with several key differences requiring careful attention during registration, including the necessity for local data, language requirements, and specific analysis conditions. Consultation and strategic planning are essential for ensuring the efficiency and success of drug approval processes in Japan.

Drug lag refers to the phenomenon where newly developed drugs take longer to become available in a specific country compared to other countries after they have been approved. This delay can occur due to various factors, including the length of regulatory approval processes, differences in clinical trial requirements, and market access barriers. In Japan, for instance, the prolonged timeline for reviewing New Drug Applications (NDA) might contribute to drug lag, as the review process can take around 12 months, which is longer compared to some regions such as the US, where it generally takes around 10 months.

Drug lag can significantly affect global access to innovative drugs in several ways:

  1. Delays in Availability: Countries experiencing drug lag will have delayed access to newly approved medicines, meaning patients may have to wait longer for effective treatments.

    • This can lead to prolonged suffering for patients who might benefit from those drugs sooner.

  2. Inequities in Healthcare: Drug lag can exacerbate health inequalities between countries with faster regulatory processes and those with slower systems.

    • Wealthier nations may gain access to innovative therapies more swiftly than poorer nations, disproportionately affecting global health outcomes.

  3. Economic Impacts: Countries that experience drug lag may also face economic consequences as they miss out on the benefits of new treatments that could improve public health and productivity.

    • The delay in access can lead to higher overall healthcare costs due to complications arising from untreated conditions.

  4. Impact on Research and Development: Pharmaceutical companies might be discouraged from investing in R&D for therapies targeting specific markets with known drug lag issues.

    • This could lead to fewer innovative drugs being developed for patients in those regions, eventually creating a cycle of disadvantage.

  5. Changes in Market Dynamics: Drug lag can influence the strategies pharmaceutical companies adopt when launching drugs globally.

    • Companies may prioritize launch in countries with more efficient processes to maximize their return on investment, further sidelining countries facing significant lag.

In Japan, drug lag affects the availability of innovative medications in several specific ways:

  1. Delays in Availability: Patients may have to wait longer for access to new treatments as the review process for New Drug Applications (NDA) can take approximately 12 months, compared to around 10 months in the US.

  2. Inequities in Healthcare: This lag can contribute to health disparities between Japan and countries with quicker approval processes, limiting access to cutting-edge therapies for Japanese patients.

  3. Economic Impacts: The delayed availability of effective treatments can lead to increased healthcare costs due to complications arising from untreated conditions, affecting both individuals and the healthcare system.

  4. Impact on R&D Investment: Pharmaceutical companies may be less inclined to invest in developing therapies targeted at the Japanese market due to the known delays, potentially leading to fewer innovative drugs being developed for patients in Japan.

  5. Market Dynamics: Drug lag may cause companies to prioritize launches in countries with faster regulatory systems, further delaying access to new therapies for Japanese patients, thereby impacting the overall health outcomes in the nation.

  1. Harmonizing Regulatory Processes:

    • Streamlining and harmonizing regulatory requirements across countries to facilitate faster approvals.

    • Implementing mutual recognition agreements (MRAs) between countries to accept each other's data and conclusions on safety and effectiveness.

  2. Improving Consultation and Support:

    • Providing early consultation services to pharmaceutical companies to navigate the approval process more effectively.

    • Establishing clearer guidelines and timelines for drug approvals to set realistic expectations for both companies and patients.

  3. Implementing Fast-Track Approvals:

    • Offering accelerated pathways for drugs that address unmet medical needs or offer significant advancements over existing treatments.

    • Prioritizing the review of orphan drugs and those for rare diseases.

  4. Enhanced Collaborative Research:

    • Promoting collaboration between international regulatory bodies and organizations to share research data and streamline clinical trial processes.

    • Facilitating global clinical trials that comply with multiple regulatory requirements to generate data acceptable across jurisdictions.

  5. Investing in Regulatory Capacity:

    • Strengthening the capacities of regulatory agencies in lagging countries by providing training and resources.

    • Ensuring regulatory bodies have the necessary manpower and technology to efficiently process applications.

  6. Encouraging Local Data Studies:

    • Supporting the conduct of clinical trials within countries to generate local data, thus potentially speeding up the approval process.

    • Incentivizing pharmaceutical companies to conduct studies that help overcome region-specific barriers to drug approval.

  7. Raising Awareness and Advocacy:

    • Increasing public awareness of drug lag issues and advocating for policy changes at national and international levels.

    • Engaging stakeholders, including patients, healthcare providers, and policymakers, to prioritize the reduction of drug lag in their agendas.

  8. Market Access Initiatives:

    • Implementing strategies to ensure that once drugs are approved, they swiftly move to market availability and reimbursement.

    • Coordinating efforts between health authorities and insurers to streamline market access post-approval.